Literature DB >> 3170024

Familial and sporadic breast cancer cases in Iceland: a comparison related to ABO blood groups and risk of bilateral breast cancer.

L Tryggvadottir1, H Tulinius, J M Robertson.   

Abstract

This study was aimed at determining whether the familial clustering often observed in breast cancer is associated with genetic factors. We compared familial and sporadic breast cancer cases with respect to ABO blood group distribution and the risk of bilateral disease, using the data from the Icelandic Cancer Registry which contains genealogical information for about 30% of the breast cancer cases diagnosed in Iceland since 1911. Cases were classified as familial if at least one first-degree relative had breast cancer. Using this criterion, we identified 184 familial cases and 572 sporadic cases. The familial cases had a 2-fold higher prevalence of blood group B than did the sporadic cases, and the frequency of this blood group in non-affected relatives of cases was significantly reduced. Familial cases were about 2.7 times more likely to suffer from bilateral breast cancer than were the sporadic patients. These results support the presence of a genetic factor in the etiology of familial breast cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170024     DOI: 10.1002/ijc.2910420405

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  ABO blood group and breast cancer incidence and survival.

Authors:  Margaret A Gates; Mousheng Xu; Wendy Y Chen; Peter Kraft; Susan E Hankinson; Brian M Wolpin
Journal:  Int J Cancer       Date:  2012-02-10       Impact factor: 7.396

Review 2.  Blood group antigens: molecules seeking a function?

Authors:  P Greenwell
Journal:  Glycoconj J       Date:  1997-02       Impact factor: 2.916

3.  Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society.

Authors:  Sungmin Park; Ku Sang Kim; Jeong-Soo Kim; Wonshik Han; Byeong-Woo Park; Seokwon Lee; Ye Won Jeon; Se Kyung Lee; Jonghan Yu; Jeong Eon Lee; Seok Won Kim; Seok Jin Nam
Journal:  Med Oncol       Date:  2017-05-12       Impact factor: 3.064

4.  Study of a single BRCA2 mutation with high carrier frequency in a small population.

Authors:  S Thorlacius; S Sigurdsson; H Bjarnadottir; G Olafsdottir; J G Jonasson; L Tryggvadottir; H Tulinius; J E Eyfjörd
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

5.  Neoplastic diseases in families of breast cancer patients.

Authors:  H Tulinius; G H Olafsdottir; H Sigvaldason; L Tryggvadottir; K Bjarnadottir
Journal:  J Med Genet       Date:  1994-08       Impact factor: 6.318

6.  Is ABO blood group a risk or prognostic factor for patients with endometrioid endometrial cancer? A retrospective analysis in Germany.

Authors:  Georgios Gitas; Louisa Proppe; Ibrahim Alkatout; Dimitrios Tsolakidis; Achim Rody; Christos Kotanidis; Sascha Baum
Journal:  Blood Transfus       Date:  2020-06-04       Impact factor: 3.443

7.  A clinicopathological analysis of breast cancer in patients with a family history.

Authors:  T Fukutomi; Y Kobayashi; T Nanasawa; H Yamamoto; H Tsuda
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

8.  ABO blood type is associated with endometrial cancer risk in Chinese women.

Authors:  Wang-Hong Xu; Wei Zheng; Yong-Bing Xiang; Xiao-Ou Shu
Journal:  Chin J Cancer       Date:  2011-11

9.  Breast cancer incidence in Greek women in relation to ABO blood groups and Rh factor.

Authors:  Michael Stamatakos; Konstantinos Kontzoglou; Panagiotis Safioleas; Constnatinos Safioleas; Christina Manti; Michael Safioleas
Journal:  Int Semin Surg Oncol       Date:  2009-08-18

10.  BRCA2 mutation carriers, reproductive factors and breast cancer risk.

Authors:  Laufey Tryggvadottir; Elinborg J Olafsdottir; Sigfridur Gudlaugsdottir; Steinunn Thorlacius; Jon G Jonasson; Hrafn Tulinius; Jorunn E Eyfjord
Journal:  Breast Cancer Res       Date:  2003-06-24       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.